Replies to post #560257 on NorthWest Biotherapeutics Inc (NWBO)

[X Master]

Hydro,

Trial Registration ClinicalTrials.gov Identifier: NCT00045968i

In this study, adding DCVax-L to SOC resulted in clinically meaningful and statistically significant extension of survival for patients with both nGBM and rGBM compared with contemporaneous, matched external controls who received SOC alone.

[HyGro]

Guess you missed the Optune trial results in JAMA (not Oncology).

Unprecedented 5-year survival data for newly diagnosed glioblastoma from the EF-14 trial published in JAMA
Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.
Journal of the American Medical Association
Stupp R, Taillibert S, Kanner A, et al.
2017;318(23):2­3­0­6­-­2­3­1­6.
Copyright 2017 American Medical Association. All rights reserved.

Interim analysis of the EF-14 trial: Pivotal phase 3 data for newly diagnosed glioblastoma published in JAMA
Maintenance therapy with Tumor-Treating Fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial.
Journal of the American Medical Association
Stupp R, Taillibert S, Kanner AA, et al.
2015;314(23):2­5­3­5­-­2­5­4­3.
Copyright 2015 American Medical Association. All rights reserved.